Trial ID or NCT#



not recruiting iconNOT RECRUITING


An open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with acute myelogenous leukemia (AML), high-grade myelodysplastic syndrome (MDS). The patient population will consist of adults previously diagnosed with AML including high-grade MDS for which standard curative, life-prolonging treatment does not exist or is no longer effective.

Official Title

An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jason Gotlib
Hematologist, Medical oncologist, Leukemia specialist
Professor of Medicine (Hematology)
Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist

Contact us to find out if this trial is right for you.


Cancer Clinical Trials Office
(650) 498-7061